![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CTSW |
Gene summary for CTSW |
![]() |
Gene information | Species | Human | Gene symbol | CTSW | Gene ID | 1521 |
Gene name | cathepsin W | |
Gene Alias | LYPN | |
Cytomap | 11q13.1 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | P56202 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1521 | CTSW | C21 | Human | Oral cavity | OSCC | 2.33e-16 | 5.77e-01 | 0.2678 |
1521 | CTSW | C38 | Human | Oral cavity | OSCC | 3.10e-09 | 1.10e+00 | 0.172 |
1521 | CTSW | C46 | Human | Oral cavity | OSCC | 1.64e-03 | 1.18e-01 | 0.1673 |
1521 | CTSW | LN22 | Human | Oral cavity | OSCC | 5.72e-05 | 8.23e-01 | 0.1733 |
1521 | CTSW | LN38 | Human | Oral cavity | OSCC | 1.54e-03 | 3.97e-01 | 0.168 |
1521 | CTSW | EOLP-2 | Human | Oral cavity | EOLP | 6.16e-03 | 2.43e-01 | -0.0203 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0421018 | Oral cavity | OSCC | Apoptosis | 101/3704 | 136/8465 | 3.34e-13 | 7.00e-12 | 3.56e-12 | 101 |
hsa041425 | Oral cavity | OSCC | Lysosome | 87/3704 | 132/8465 | 1.97e-07 | 1.35e-06 | 6.86e-07 | 87 |
hsa0421019 | Oral cavity | OSCC | Apoptosis | 101/3704 | 136/8465 | 3.34e-13 | 7.00e-12 | 3.56e-12 | 101 |
hsa0414212 | Oral cavity | OSCC | Lysosome | 87/3704 | 132/8465 | 1.97e-07 | 1.35e-06 | 6.86e-07 | 87 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CTSW | SNV | Missense_Mutation | novel | c.831N>G | p.Ile277Met | p.I277M | P56202 | protein_coding | tolerated(0.11) | benign(0.262) | TCGA-CR-6481-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | paclitaxel | SD |
CTSW | SNV | Missense_Mutation | rs748607117 | c.784N>A | p.Val262Met | p.V262M | P56202 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-CV-A6K1-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CTSW | SNV | Missense_Mutation | novel | c.760N>A | p.Leu254Met | p.L254M | P56202 | protein_coding | deleterious(0.02) | possibly_damaging(0.648) | TCGA-QK-A6VB-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CTSW | SNV | Missense_Mutation | rs533711333 | c.595G>A | p.Ala199Thr | p.A199T | P56202 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
CTSW | SNV | Missense_Mutation | novel | c.217N>A | p.Ala73Thr | p.A73T | P56202 | protein_coding | deleterious(0) | possibly_damaging(0.833) | TCGA-BR-6709-01 | Stomach | stomach adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
CTSW | SNV | Missense_Mutation | c.1066N>G | p.Lys356Glu | p.K356E | P56202 | protein_coding | tolerated(0.12) | benign(0.062) | TCGA-CD-A4MG-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
CTSW | SNV | Missense_Mutation | rs150421438 | c.586G>A | p.Val196Ile | p.V196I | P56202 | protein_coding | tolerated(0.12) | benign(0.037) | TCGA-CD-A4MI-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
CTSW | SNV | Missense_Mutation | c.758N>G | p.Tyr253Cys | p.Y253C | P56202 | protein_coding | deleterious(0.01) | benign(0.1) | TCGA-CG-5721-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
CTSW | SNV | Missense_Mutation | c.943C>G | p.Gln315Glu | p.Q315E | P56202 | protein_coding | tolerated(1) | benign(0.026) | TCGA-D7-5578-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
CTSW | SNV | Missense_Mutation | c.596C>T | p.Ala199Val | p.A199V | P56202 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-HU-8602-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Chemotherapy | xeloda | CR |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |